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The replication of vaccinia virus was reduced by 3 logs in cells that had been treated before and during infection with a
concentration of N-(phosphonoacetyl)-L-aspartate (PALA) which lowered the UTP and CTP to 5 and 20% of controls, respec-
tively, without affecting cell viability. The antiviral activity of PALA was reversed with uridine, indicating that it was entirely
due to the diminution in pyrimidine nucleotides. Analysis of viral proteins revealed prolonged synthesis of some early stage
species but a drastic reduction in late stage species, even though the nucleotide concentrations remained relatively constant
throughout the infection. Although the gene expression pattern resembled that caused by a potent inhibitor of DNA synthesis,
viral DNA accumulation was reduced by only 60%. Very little of the DNA made in the presence of PALA was converted to
genome length molecules. The effect of PALA on transcription of early genes was complex: there was a twofold increase
in the amount of a relatively short mRNA of 500 nucleotides but a two- to threefold decrease in the amount of a 4300-
nucleotide mRNA encoding the largest subunit of RNA polymerase. In contrast, PALA severely inhibited the accumulation
of viral intermediate and late stage mRNAs. The extreme sensitivity of vaccinia virus to PALA and the differential effects
of the drug on viral gene expression result from the cascade mechanism of viral gene regulation. q 1997 Academic Press
INTRODUCTION bamoyl L-aspartate. PALA is a stable transition state ana-
log of the latter reaction, binding to aspartate carbamoyl
The poxviruses are large DNA viruses that replicate
transferase about 1000 times more tightly than carbamoyl
and transcribe their genomes within the cytoplasm of
phosphate, the most tightly bound substrate. PALA enters
infected cells (Moss, 1996). As the corresponding cellular
mammalian cells by fluid-phase endocytosis, with cyto-
processes occur in the nucleus, poxviruses encode many
solic concentrations approaching that of the extracellular
of the enzymes directly involved in viral mRNA and DNA
medium (Swyryd et al., 1974; White and Hines, 1984). In a
synthesis. The transcription of viral early genes is medi-
dose-, time-, and cell-dependent manner, PALA decreases
ated by proteins that are brought into the cell within the
UTP, CTP, dCTP, dTTP, and dGTP pools whereas ATP,
core of virions, whereas de novo RNA synthesis and
GTP, and dATP pools are either unaffected or elevated
protein synthesis are required for DNA replication and
(Chan and Howell, 1985; Grant et al., 1982; Hunting and
transcription of viral intermediate and late genes. Vac-
Henderson, 1982; Moyer et al., 1982). PALA is active
cinia virus also encodes several nucleotide biosynthetic
against murine solid tumors (Johnson et al., 1976, 1978),
enzymes, even though the cellular homologs are cyto-
although clinical anti-cancer trials were disappointing
solic. These viral proteins include thymidine kinase (TK),
(Grem et al., 1988). The use of PALA as a broad spectrum
thymidylate kinase, and ribonucleotide reductase.
antiviral agent has been suggested (Blough et al., 1993;
In this report, we describe the effects on vaccinia virus
Wyde et al., 1995). Here, we show that subtoxic doses of
mRNA and DNA synthesis that accompany alterations in
PALA, which reduced the UTP and CTP pools in cultured
the intracellular pyrimidine nucleotide pools. These pertur-
simian cells, had differential effects on vaccinia virus gene
bations were produced with N-(phosphonoacetyl)-L-aspar-
expression and prevented infectious virus formation. A
tate (PALA), a rationally synthesized compound that acts
preliminary account of this work has been presented (Kat-
as a potent inhibitor of aspartate carbamoyl transferase
safanas et al., 1994).
(Collins and Stark, 1971). The latter enzyme catalyzes the
second step of de novo pyrimidine biosynthesis: conden-
MATERIALS AND METHODSsation of L-aspartate and carbamyl phosphate to form car-
Cells and viruses
1 To whom reprint requests should be addressed at NIAID, NIH, 4
Suspended HeLa S-3 cells (ATCC CCL2.2) were grownCenter Drive, MSC 0445, Building 4, Room 229, Bethesda MD, 20892-
0445. Fax: (301) 480-1147. Email: bmoss@nih.gov. in Eagle’s spinner medium (Quality Biologicals) supple-
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mented with 5% horse serum; monolayer cultures of BS- was added to triplicate wells to achieve the final desired
concentrations. Each day, 10 ml of MTT (Sigma, 5 mg/mlC-1 cells (ATCC CCL26) were propagated in minimal
esential medium (MEM; Quality Biologicals) with 10% fe- in phosphate-buffered saline) was added to the wells of
one plate which was then incubated at 377 for 4 hr. Reac-tal calf serum. Stocks of vaccinia virus strain WR (ATCC
VR1354) and vSC-8, a TK-negative virus in which the tions were terminated by adding 0.1 ml of 0.01 M HCl
containing 10% sodium dodecyl sulfate (SDS). Incuba-lacZ gene was inserted into the TK coding sequences
(Chakrabarti et al., 1985), were prepared in HeLa cell tions were continued overnight at 377, and the ab-
sorbance at 570 nm was measured.monolayers using MEM and 10% serum. Vaccinia virus
was purified from infected HeLa cell suspension cultures
Analysis of metabolically labeled proteinsby sucrose density gradient centrifugation (Earl et al.,
1991). PALA was obtained from U.S. Biosciences, Inc.
BS-C-1 cells were seeded into six-well plates; PALA
(West Conshocken, PA).
(50 mg/ml) was added 6 hr later. After 16 hr of PALA
treatment, the medium was removed and the cells inDetermination of ribonucleotide pools
each well were infected with purified vaccinia virus (15
PFU/cell) in 1 ml of MEM supplemented with 2.5% serumConfluent monolayers of PALA-treated or untreated BS-
C-1 cells in 80-cm2 flasks were washed three times with and 50 mg/ml of PALA. After 30 min, the virus inoculum
was removed and the cells in each well were covered3 ml of ice-cold phosphate-buffered saline (PBS) and
mixed with 3 ml of 0.5 N perchloric acid. After 20 min at with 2 ml of fresh medium containing PALA. At intervals,
calculated from the time of virus addition, the cells were47, the acid-soluble material was obtained by centrifuga-
tion and mixed with 2 vol of trichlorotrifluoroethane:tri- washed once with methionine-deficient MEM and then
incubated with 1 ml of the latter containing 30 mCi ofn-octylamine (3.4:1.5 v/v), and the aqueous fraction was
neutralized with sodium hydroxide. The samples were fro- [35S]methionine. After 30 min, the labeled medium was
removed and the cells were washed once with PBS andzen on dry ice, lyophilized, and stored at 0707. Immedi-
ately prior to analysis, the residue was suspended in water then lysed with 300 ml of 60 mM Tris–HCl (pH 6.8), 2%
SDS, 1% b-mercaptoethanol, 10% glycerol, and 0.1 mg/and filtered through a 0.45-mm Gelman acrodisc filter
(LC13, PVDF). Analysis was carried out by high-pressure ml bromophenol blue. The samples were heated at 957
for 10 min, passed 10 times through a 25-gauge needle,liquid chromatography (HPLC) using a U6K injector, a
600E pump, a 996 photodiode detector set to monitor 240 and applied to an SDS gel with 6 and 12% polyacrylamide
in the stacking and separating layers, respectively.to 300 nm, and Millenium software (Waters). A 110-mm
Whatman Partisphere 5 SAX column was developed with
DNA hybridizationthree solutions as the mobile phase: buffer A was HPLC-
grade water, buffer B was 0.2 M ammonium phosphate,
BS-C-1 cells were seeded on 6-well plates, treated
pH 3.8, and buffer C was 0.4 M ammonium phosphate,
with PALA (50 mg/ml) or cytosine arabinoside (araC; 40
pH 3.8. An isocratic gradient of 15% A/85% B was run at
mg/ml) for 16 hr, and then infected in the presence of
2.6 ml/min for 20 min, followed by a linear gradient to 10%
drug with purified vaccinia virus (15 PFU/cell). At inter-
A/90% B over 12 min and then to 100% B over 6 min. A
vals, cells were harvested by scraping, collected by cen-
linear gradient to 100% C at 3 ml/min was run over 5 min,
trifugation, and resuspended in 300 ml of TE (10 mM
followed by an isocratic gradient of 100% C for 7 min; the
Tris–HCl, 1 mM EDTA, pH 8.0). Each sample was incu-
column was equilibrated under initial conditions for 10
bated with 50 ml of 0.1 M NaCl, 100 mM Tris–HCl, 1 mM
min prior to the next run. Each nucleotide was monitored
EDTA, pH 8.0; 25 ml of 20% SDS; and 50 ml of 1 mg/ml
at its optimal wave length: GTP, 252 nm; UTP and ATP,
proteinase K overnight at 377. After phenol/chloroform
260 nm; and CTP, 278 nm. The retention times in minutes
extraction, the DNA was precipitated with 0.1 of the sam-
were as follows: CTP, 17; UTP, 29; ATP, 33; and GTP, 47.
ple volume of 3 M sodium acetate and 2 sample volumes
A standard curve for peak area as a function of quantity
of ethanol. The precipitates were dried and resuspended
of each ribonucleoside triphosphate was generated by
in TE and the DNA concentrations determined spectro-
injecting known amounts and fitting the curve to a first-
photometrically. To 30 ml of each sample, 52 ml of H2O,order linear regression.
6.6 ml of Tris–HCl (pH 8.0), and 6.6 ml of EDTA (pH 8.0)
were added, and the mixture was boiled for 10 min. AfterCell viability assay
incubation with 13.2 ml of 10 N NaOH at room tempera-
ture for 10 min, the samples were placed on ice andViable cell numbers were determined by the modified
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro- ammonium acetate (69.3 ml of a 2 M concentration and
61.4 ml of a 1 M concentration) was added. A slot blotmide thiazolyl blue (MTT) oxidation procedure (Mos-
mann, 1983; Tada et al., 1986). BS-C-1 cells (5 1 104) apparatus, Minifold II (Schleicher and Schuell), was used
to apply the sample to a nylon membrane (Hybond-N/,were distributed into 96-well plates (Costar). On the fol-
lowing day, the monolayers were confluent and PALA Amersham) that had been wet with H2O and then 1 M
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ammonium acetate. The DNA was bound to the mem- in a Boehringer Mannheim random-primed DNA labeling
kit and hybridization was performed as described abovebrane using a UV crosslinker (Stratalinker, Stratagene).
The immobilized DNA was treated with 51 SSC (0.75 M for immobilized DNA. RNA was visualized by autoradiog-
raphy and a Betagen Betascope 603 blot analyzer wasNaCl, 0.075 M sodium citrate), 51 Denhardt’s solution (1
mg/ml Ficoll, 1 mg/ml polyvinylpyrrolidone, 1 mg/ml bo- used for quantitation.
Nuclease protection analyses were carried out as fol-vine serum albumin), and 0.02 mg/ml salmon sperm DNA
at 657 for 1 hr. Two cosmids containing vaccinia virus lows. Antisense RNA probes labeled with [a-32P]UTP
(3000 Ci/mmol, 10 mCi/ml) were synthesized using bacte-DNA sequences were labeled using a random-primed
DNA labeling kit (Boehringer Mannheim). Hybridization riophage T7 RNA polymerase to transcribe DNA se-
quences downstream of the T7 f10 promoter (Baldickwas for approximately 12 hr at 657. Following hybridiza-
tion, the filters were washed twice in 21 SSC, 0.1% SDS and Moss, 1993). The template for the vaccinia virus
growth factor (VGF) gene consisted of a 638-bp HincII–at room temperature for 10 min, once in 11 SSC con-
taining 0.1% SDS at 657 for 15 min, and twice in 0.11 AccI fragment cloned into pGEM-3Z (Promega). After di-
gestion with EcoRI, run-off transcription generated a 678-SSC containing 0.1% SDS at 657 for 10 min. The hybrid-
ized probe was visualized by autoradiography and quan- base probe that should protect 316 bases of the 5* end
of the viral mRNA. The template for the 11-kDa structuraltitated with a Betagen Betascope 603 blot analyzer.
protein gene encoded by open reading frame (ORF) F17R
Electrophoresis of DNA consisted of a 670-bp BamHI–HindIII fragment cloned
into pGEM-4Z (Promega). After digestion with BamHI,
Vaccinia virus-infected BS-C-1 cells, in 6-well plates,
run-off transcription generated a 682-base probe that
were harvested by scraping and collected by low-speed
should protect 126 bases of the 5* end of the viral mRNA.
centrifugation. The cells were washed with PBS and re-
The template for the late transcription factor VLTF-1 en-
suspended in 1 ml of STE (100 mM NaCl, 50 mM EDTA,
coded by ORF G8R consisted of a 500-bp EcoRI–HindIII
20 mM Tris–HCl, pH 8.0). An equal volume of 2% low-
fragment cloned into pGEM4Z. After digestion with EcoRI,
melting-point agar in STE was added and the resulting
run-off transcription generated a 500-base probe which
mixture was added to wells of a mold that had been
would protect 300 bases of the 5* end of the viral mRNA.
cooled on ice. The solidified agar plugs were incubated
Total cell RNA (3 mg) was hybridized overnight at 427 to
with 1% Sarkosyl, 0.5 M EDTA, and 0.5 mg/ml of protein-
a molar excess of labeled complementary RNA probes
ase K at 377 for 3 days with daily solution changes and
in 30 ml of 40 mM Pipes (pH 7.5), 0.4 M NaCl, 1 mM
then with TE for 2 days with twice-daily solution changes.
EDTA, deionized 80% formamide. Digestion was in 300
Some plugs were then incubated overnight with NotI.
ml of 10 mM Tris–HCl (pH 7.5), 5 mM EDTA, 0.3 mM
Small slices of the agar plugs were inserted into wells
NaCl with RNase A (4 mg/ml) and RNase T1 (10 units/
of 1% agarose (Beckman Gene Line LE agarose). Electro-
ml) at room temperature for 1 hr. Protected probe frag-
phoresis was carried out in a Beckman Gene Line Trans-
ments were analyzed by electrophoresis on a 6% poly-
verse Alternating Field Electrophoresis apparatus in 10
acrylamide/8 M urea gel and visualized by autoradiogra-
mM Tris–acetate, 0.25 mM EDTA, pH 8, for 21 hr at 140
phy. A Betagen Betascope 603 blot analyzer was used
mA with a switching time of 15 sec.
for quantitation.
For Northern blot analysis, total RNA was purified asRNA purification and analysis
above and 10 mg was incubated for 15 min at 657 in Mops
buffer (0.02 M Mops (pH 7.0), 8 mM sodium acetate,BS-C-1 cells (2.5 1 106 per well in a 6-well plate) were
incubated for 16 hr with PALA, AraC, or no drug and in- 1 mM EDTA) containing 2.2 M formaldehyde and 50%
formamide and applied to a 1% agarose gel containingfected with purified vaccinia virus at a multiplicity of 15
PFU/cell. At intervals, the medium was aspirated and the Mops buffer with 2.2 M formaldehyde and electropho-
resed with constant buffer circulation. The gel was thencells were washed with PBS. RNA was purified by the
acid guanidinium thiocyanate–phenol–chloroform method immersed in diethyl pyrocarbonate-treated water to re-
move the formaldehyde and then briefly stained withusing 1 ml of RNAzol (Cinna Scientific, Inc.) as described
by the manufacturer. Approximately 1 mg of RNA was ob- ethidium bromide. After transferring the RNA to a nylon
membrane, hybridizations were carried out at 687 in 61tained per 105 BS-C-1 cells and stored in TE buffer at0707.
For hybridization analysis, 5 ml of RNA sample was SSC, 21 Denhardt’s reagent, 0.1% SDS with [a-32P]UTP-
labeled riboprobes prepared by in vitro transcription ofmixed with 5 ml of H2O, 20 ml of 100% formamide, 7 ml
of 37% formaldehyde, and 2 ml of 201 SSC and then PCR products containing a T7 promoter. For the RNA
encoding the large subunit of RNA polymerase, two ribo-applied to a slot blot apparatus containing a nylon trans-
fer membrane (Hybond-N/, Amersham) that had been probes were synthesized: one riboprobe of 310 nucleo-
tides corresponded to the 5* end of the mRNA; the otherwet with 201 SSC for 1 hr. The RNA was bound to the
membrane using the Stratalinker UV crosslinker. The riboprobe was 297 nucleotides and corresponded to the
3* end. For the RNA encoding VGF, the 5* and 3* ribo-vaccinia virus DNA probe was labeled as recommended
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GTP pools were unaffected at all PALA concentrations
(data not shown). For subsequent experiments, unless
otherwise mentioned, the standard condition for PALA
treatment was 0.167 mM for 16 hr prior to infection. PALA
was routinely maintained at the same concentration dur-
ing vaccinia virus infection, but the UTP and CTP concen-
trations exhibited only a slight further reduction even
after 24 hr (data not shown).
Effects of PALA on cell viability
The viability of nearly confluent BS-C-1 cells in the
presence of PALA was determined by the quantitative
colorimetric MTT procedure, which uses a tetrazolium
salt to measure mitochondrial oxidative enzyme activity
of living but not dead cells (Mosmann, 1983; Tada et al.,FIG. 1. Effect of PALA concentration on the UTP and CTP pools of
uninfected BS-C-1 cells. At 16 hr after addition of indicated amounts 1986). Over a 48-hr period, even the highest concentra-
of PALA, the ribonucleoside triphosphate pools were determined by tion of PALA (1 mM) tested had no measurable effect on
HPLC. The 100% values are the nucleotide concentrations without drug. the MTT assays (Fig. 3). MTT values of control cells, and
Standard error bars are shown.
cells treated with concentrations of PALA below 0.334
mM, increased at 72 hr as a result of cell proliferation;
probes were 262 and 217 nucleotides, respectively. The the MTT values remained constant at higher concentra-
labeled RNA probes were used directly for hybridization. tions of PALA. At 96 hr, the MTT values decreased mod-
RNA was visualized by autoradiography, and a Betagen estly in cells treated with more than 0.033 mM PALA.
Betascope 603 blot analyzer was used for quantitation.
Effects of PALA on viral replication
RESULTS
At PALA concentrations that had no discernible effect
Reduction of pyrimidine nucleotide pools by PALA on the viability of BS-C-1 cells, the formation of infectious
vaccinia virions was severely inhibited. Under one-stepThe effect of PALA on the ribonucleoside triphosphate
growth conditions, the 48-hr yield of wild-type (strain WR)pools of uninfected BS-C-1 cells was determined by
vaccinia virus was reduced by 3 logs at a PALA concen-HPLC. The amounts of UTP, CTP, ATP, and GTP per 106
tration of 0.167 mM (Figs. 4A and 4B). A TK0 virus deriva-untreated cells were 5.5 { 0.7, 1.6 { 0.2, 14.0 { 1.2, and
tive (vSC-8) was even more sensitive to PALA (Fig. 4A),2.86 { 0.02 nmol, respectively. Reductions in UTP and
presumably due to loss of the virus-enhanced salvageCTP were evident with 0.0167 mM (5 mg/ml) PALA and
pathway for thymidylate synthesis.maximal effects occurred with five or more times that
amount (Fig. 1). With 0.167 mM PALA, the reduction was
Uridine reverses the antiviral effect of PALAsignificant by 4 hr and near maximal by 16 hr, at which
time the UTP and CTP pools were 5 and 20% of control The mechanism of the antiviral effect of PALA was
investigated by determining the ability of uridine to pre-values, respectively (Fig. 2). As expected, the ATP and
FIG. 2. Reduction in UTP and CTP pools of uninfected BS-C-1 cells as a function of time after addition of PALA. Ribonucleoside triphosphate
pools were determined by HPLC. The control values represent the nucleotide concentrations in the absence of drug.
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FIG. 3. Effect of PALA on the viability of uninfected BS-C-1 cells. Nearly confluent BS-C-1 cells were treated with the indicated concentrations of
PALA and cell viability was determined by the MTT method at the indicated hours.
vent the inhibition of virus replication in cells that had and the AraC patterns are due to the persistence of host
protein labeling in the presence of AraC but not PALA.been pretreated with 0.167 mM PALA for 16 hr. When
0.1 mM uridine was given at the time of infection, while Controls showed that PALA had no discernible effect on
the synthesis of proteins in uninfected cells over the 20-maintaining PALA, the yields for TK/ and TK0 viruses
were normal in contrast to the 2.5 to 3.5 log inhibition hr period (Fig. 6).
that occurred in the absence of uridine (Fig. 5). With 0.1
Effect of PALA on the replication and processing ofmM deoxyuridine, thymidine, or deoxycytidine, however,
viral DNAthe virus yield was only slightly increased. The ability of
uridine to completely reverse the effects of PALA implies Replication of the vaccinia viral genome depends on
that the antiviral activity operates solely through a reduc- the de novo synthesis of viral early enzymes. Therefore,
tion in the pyrimidine nucleotide pools. PALA could inhibit DNA replication directly by lowering
the pyrimidine nucleotide pool or indirectly by inhibiting
Effect of PALA on viral protein synthesis
the synthesis of viral enzymes. The effect of PALA on
viral DNA synthesis, measured by hybridization to a 32P-Vaccinia virus genes can be divided into three classes:
early genes are expressed before DNA replication and labeled probe, was dose-dependent but less effective
than AraC at a similar molar concentration (Fig. 7A). Withintermediate and late genes are successively expressed
after DNA replication. The temporal regulation of viral 0.167 mM PALA, accumulation of viral DNA was delayed
and reduced by about 60% at 24 hr (Fig. 7B), an amountgene expression was analyzed by SDS–polyacrylamide
gel electrophoresis of extracts from cells that had been that seemed insufficient to account for either the virtual
absence of viral late protein synthesis or the 2 to 3 logpulse-labeled with [35S]methionine during the course of
infection. Inspection of the no drug (ND) lanes of the drop in virus yield.
The large 180-kb genome of vaccinia virus can be re-autoradiograph in Fig. 6 revealed several presumptive
viral early proteins of less than 45 kDa at 2 hr and a solved, by pulse-field gel electrophoresis, from concate-
meric replicative forms which remain in the sample appli-wide size range of intermediate or late proteins at 6 hr
and times thereafter. In the presence of AraC, an inhibitor cation zone (DeLange, 1989; Merchlinsky and Moss, 1989).
The replicative forms have not been characterized butof DNA replication, the 2-hr early pattern persisted with-
out the appearance of late proteins and with incomplete probably include branched molecules. At 24 hr after infec-
tion in the absence of PALA, most of the viral DNA was inshut-off of host protein synthesis. The pattern with PALA
treatment resembled that occurring with AraC, i.e., viral the form of genome-length molecules (Fig. 8, lane 1). In
contrast, only a small amount of the viral DNA from cellsearly protein synthesis persisted and viral late proteins
did not appear. The major differences between the PALA infected in the presence of 0.167 mM PALA was genome
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unit-length genomes results in two fragments of 140 and
40 kb. The expected fragments were formed by NotI di-
gestion of DNA formed in the absence and in the pres-
ence of PALA (Fig. 8, lanes 2 and 4). In both cases some
residual genome-length molecules remained, probably
as a result of incomplete in situ cleavage by NotI. How-
ever, genome-length molecules and multimers could
arise from complete or incomplete NotI cleavage of con-
catemeric DNA, as apparently occurred with the DNA
from the temperature-sensitive mutant (Fig. 8, lane 7).
We concluded that PALA partially inhibits the synthesis
of viral DNA and the processing of replicative forms.
Effects of PALA on viral mRNA synthesis
The effect of PALA on the amounts of total viral RNA
present in infected cells at various times after infection
was determined by hybridization with 32P-labeled viral
DNA. In untreated cells, the amount of viral RNA was
maximal at 6 hr and remained constant over the next 18
hr (Fig. 9). PALA had little effect on the total viral RNA
accumulation for the first 2 hr but prevented the subse-
quent increase that occurred in untreated cells. The pat-
tern with PALA was similar to that occurring in the pres-
ence of AraC, suggesting that PALA also preferentially
inhibited transcription of intermediate and/or late genes.
The transcription products of well-characterized early,
intermediate, and late genes were analyzed next. Unlike
FIG. 4. Effect of PALA concentration on the replication of vaccinia
virus. BS-C-1 cells were treated with indicated concentrations of PALA
for 16 hr and then infected in the presence of drug with 5 PFU/cell of
vaccinia virus. (A) Cells were infected with wild-type vaccinia virus [WT
(TK/)] or a thymidine kinase-negative recombinant vaccinia virus [vSC-
8 (TK0)]. After 48 hr, the infected cells were harvested. (B) Cells were
infected with wild-type virus and harvested at the times indicated. In
both panels, virus yields were determined by plaque assay in the ab-
sence of drug.
length; the majority remained in the sample zone, indicat-
ing a defect in DNA processing (Fig. 8, lane 3). At higher
PALA concentrations, there was also a drastic reduction
in the amount of viral DNA formed (Fig. 8, lane 5), consis-
tent with the dot blot analysis in Fig. 7. A temperature- FIG. 5. Reversal of the antiviral effect of PALA with uridine. BS-C-1
cells were treated for 16 hr with PALA and then infected with wild-typesensitive virus (Condit et al., 1983) with a defect in DNA
vaccinia virus [WT (TK/)] or a thymidine kinase-negative recombinantprocessing (DeLange, 1989; Merchlinsky and Moss, 1989)
virus [vSC-8 (TK0)] in the presence of 0.167 mM PALA alone or PALAwas examined as a control; as expected most of the viral
plus 0.1 mM uridine (U), deoxyuridine (dU), thymidine (T), or deoxycyti-
DNA remained in the sample zone (Fig. 8A, lane 7). dine (dC). The cells were harvested after 48 hr and the virus yields
The vaccinia virus genome has a single NotI restriction were determined by plaque assay in the absence of drug. The virus
yields in cells that were not treated with PALA (ND) are also shown.endonuclease site. Therefore, complete cleavage of a
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FIG. 6. Effect of PALA on vaccinia viral protein synthesis. Untreated (ND), PALA-treated, and AraC-treated BS-C-1 cells were infected with vaccinia
virus and labeled for 30 min with [35S]methionine at the times indicated. The cells were harvested immediately after the pulse-labeling and the
proteins subsequently analyzed by SDS–polyacrylamide gel electrophoresis and autoradiography. The masses (in kDa) of the protein standards
are indicated on the left. Dots were placed to the left of presumptive viral bands in the 2- and 6-hr ND lanes.
early mRNAs, most intermediate and late mRNAs are We suspected that the low concentrations of UTP and
CTP might have a greater effect on synthesis of longheterogeneous in length and fail to terminate at the ends
of their open reading frames. Therefore, we used RNase mRNAs, such as the 4300-nucleotide mRNA encoding
the large subunit of RNA polymerase, compared to theprotection assays to detect the properly initiated 5* ends
of transcripts. In the ND control, the representative early relatively short 500-nucleotide mRNA encoding VGF ana-
lyzed above. Although RNA polymerase continues to bemRNA encoding the vaccinia virus growth factor (VGF)
was most abundant at 2 hr after infection and diminished made throughout infection, we designed the experiment
so that early mRNAs were examined specifically. RNAprogressively at subsequent times, consistent with previ-
ous data (Baldick and Moss, 1993; Fig. 10). By contrast, was analyzed at 2, 3, and 4 hr after infection because
we had shown in Fig. 10 that late mRNAs are not detect-in the presence of PALA or AraC, the VGF transcript
remained abundant until at least 8 hr after infection. able at 2 hr and are made in only small amounts at 4 hr.
In this case, Northern blotting was used for detectionA representative intermediate mRNA encoding the late
transcription factor VLTF-1 (Keck et al., 1990; Wright et and quantitation of the discrete size early transcripts so
as to distinguish them from intermediate and late tran-al., 1991) was most abundant at 4 and 6 hr after infection
in the absence of drugs, whereas accumulation of the scripts which are heterogeneous in length. Probes of
about 200 to 300 nucleotides complementary to the 5*intermediate transcript was delayed and reduced with
PALA (Fig. 10). Very small amounts of the intermediate and 3* ends of the VGF transcript and similar probes
complementary to the 5* and 3* ends of the transcript fortranscript were detected in the presence of AraC.
In the absence of drugs, the late mRNA encoding the the large subunit of RNA polymerase were used. Similar
results were obtained with the 5* and 3* end probes,11-kDa virion protein product of the F17R ORF (Wittek et
al., 1984) was detected in small amounts at 4 hr after although the autoradiogaphs were more intense with the
former. At 2 hr, approximately equal amounts of the VGFinfection and was increased at subsequent times (Fig.
10). By contrast, the late transcript was barely detected transcript were detected in PALA-treated and untreated
cells, whereas at 3 and 4 hr more was detected from thein the presence of PALA and undetected in the presence
of AraC. treated cells (Fig. 11). By contast, there was less of the
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for virus replication (De Clercq, 1993). Specificity is an
advantage of the first group of inhibitors, although selec-
tion of resistant mutants can be the Achilles’ heel. The
second class of agents may be cytostatic to rapidly grow-
ing cells but relatively nontoxic to stationary cells at con-
centrations that block virus replication. A broad spectrum
of antiviral activity and the unlikely development of drug-
resistant viral mutants are potential advantages of the
latter agents. PALA, a potent inhibitor of cellular aspar-
tate carbamoyl transferase (Collins and Stark, 1971), low-
ers the intracellular concentration of pyrimidine nucleo-
tides. We demonstrated that PALA inhibited vaccinia vi-
rus replication and correlated the antiviral activity with
decreased intracellular concentrations of UTP and CTP
that did not affect the viability of stationary BS-C-1 cells.
The antiviral action was fully reversed with uridine, indi-
cating that PALA acted solely by lowering the pyrimidine
nucleotide pool. In addition, our attempts to isolate PALA-
resistant mutants by passaging vaccinia virus in the pres-
ence of increasing drug concentrations were unsuccess-
ful (our unpublished data).
Other studies indicated that PALA reduces cellular
dCTP, TTP, and dGTP in concert with UTP and CTP (Hunt-
ing and Henderson, 1982), so that direct effects on viral
DNA synthesis as well as RNA synthesis might be antici-
FIG. 7. Effect of PALA on viral DNA synthesis. BS-C-1 cells were
treated with no drug (ND) or indicated amounts of PALA or AraC for
16 hr and then infected with vaccinia virus. (A) Cells were harvested
at 24 hr after infection and the DNA was immobilized on a nylon filter
and then incubated with a 32P-labeled vaccinia viral DNA probe. The
bound radioactivity was determined by scintillation spectroscopy. (B)
Cells were harvested at the indicated times after infection. The DNA
was extracted, purified, and immobilized on a filter which was then
incubated with a 32P-labeled vaccinia viral DNA probe and counted.
mRNA encoding the RNA polymerase large subunit at
even the earliest time examined in the presence of PALA
compared to that in the absence of PALA (Fig. 11). Quan- FIG. 8. Effect of PALA on formation of genome-length DNA molecules.
Untreated (ND) BS-C-1 cells or cells treated with 0.167 or 1 mM PALAtitation of the 4-hr samples on a Betagen Betascope indi-
for 16 hr were infected with wild-type vaccinia virus or a temperature-cated that the ratio of VGF mRNA in the presence and
sensitive mutant TS21. At 24 hr after infection, the cells were mixedin the absence of PALA was approximately 2:1, whereas with molten agar, the DNA was subsequently deproteinized in situ to
the ratio for the polymerase mRNA was about 1:3. prevent shearing, and some samples were also digested with NotI.
After electrophoresis, the DNA was stained with ethidium bromide,
transferred to a nylon membrane, and hybridized to a radioactively
DISCUSSION labeled viral DNA probe, and autoradiography was performed. The film
was overexposed to show the small amount of unit-length genomes
Antiviral agents can be divided into two general formed in the presence of PALA. The asterisk indicates DNA remaining
classes: those that target virus-encoded macromole- at the application zone; the arrow indicates the unit-length 180-kb ge-
nome; arrowheads indicate 140- and 40-kDa NotI fragments.cules and those that affect cellular processes required
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FIG. 11. Northern blot analysis of early mRNAs synthesized in the
presence or absence of PALA. PALA-treated or untreated BS-C-1 cells
were infected with vaccinia virus and harvested at the indicated times.
Total RNA was isolated and equal amounts were resolved on a 1%
agarose gel containing formaldehyde. After transfer to a nylon mem-FIG. 9. Effect of PALA on viral RNA synthesis. BS-C-1 cells that were
brane, the RNAs were detected by hybridization to 32P-labeled RNAuntreated or treated with PALA or AraC were infected with vaccinia
probes of 262 and 217 nucleotides complementary to the 5* and 3* endsvirus. At intervals, the infected cells were harvested and total RNA
of the VGF transcript and similar probes of 310 and 297 nucleotideswas isolated. The purified RNA samples were immobilized on filters,
complementary to the 5* and 3* ends of the transcript for the largeincubated with a 32P-labeled vaccinia viral DNA probe, and then
subunit of RNA polymerase. An autoradiograph is shown.counted.
pated. Discriminating between effects on vaccinia viral virus-enhanced salvage pathway for thymidylate synthe-
sis, has enhanced sensitivity to PALA suggested that DNARNA and DNA synthesis is complicated, because DNA
replication is required for viral intermediate and late gene replication was adversely affected by the drug. Indeed, in
cells infected with wild-type virus, PALA inhibited viralexpression (Moss, 1993) and viral early gene expression
and late gene expression are required for the synthesis DNA synthesis in a dose-dependent manner. The degree
of inhibition at antiviral concentrations (0.167 mM), how-and processing of viral DNA (DeLange, 1989; Merchlinsky
and Moss, 1989), respectively. The finding that TK-nega- ever, was only 60%. This degree of inhibition does not tell
the full story, because DNA replication was delayed andtive vaccinia virus, with a diminished ability to use the
FIG. 10. Effect of PALA on synthesis of specific early, intermediate, and late mRNAs. BS-C-1 cells that were untreated (ND) or treated with PALA
or AraC were infected with vaccinia virus and harvested at the indicated times. Total RNA was isolated and used to hybridize with excess 32P-
labeled antisense riboprobe. After digestion with RNases, the protected probe was analyzed by electrophoresis on a 6% polyacrylamide/8 M urea
gel and visualized by autoradiography. VGF, an early RNA encoding the vaccinia virus growth factor; VLTF-1, an intermediate RNA encoding a late
transcription factor; 11K, a late RNA encoding a structural protein of 11 kDa.
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much of the DNA remained near the application zone Treatment of monkeypox might be considered in the
future since epidemics with signficant human-to-humanupon pulsed-field gel electrophoresis. We do not know
whether the block in processing of replicated DNA into transmission occurred in Zaire in 1996 and 1997
(Mwamba et al., 1997). Molluscum contagiosum virusgenome-length molecules was due to aberrant DNA struc-
tures or insufficient amounts of processing enzymes. (Porter et al., 1992; Senkevich et al., 1996) has a world-
wide distribution and commonly causes small benignThe most striking effect of PALA was the almost total
inhibition of viral late gene expression, as measured by but persistent skin lesions in infants and young adults
(Gottlieb and Myskowski, 1994). In immunodeficient in-RNA or protein synthesis. In contrast, pulse-labeling
with [35S]methionine indicated that the synthesis of dividuals, such as those with AIDS, molluscum contagi-
osum lesions become much more widespread; althoughsome early proteins was increased and prolonged as
occurs with a potent inhibitor of DNA replication. We not life-threatening, the lesions may be disfiguring so
that an effective treatment would improve the quality ofconsidered that a reduction in the pyrimidine nucleotide
pool might affect the synthesis of some early mRNAs life. Vaccinia virus also is capable of spreading exten-
sively and producing a severe infection in immunodefi-more than others. In particular, long mRNAs or mRNAs
with long pyrimidine tracts might be more sensitive than cient people (Redfield et al., 1987). It is possible that
PALA, or other pyrimidine nucleotide inhibitors (Des-other mRNAs to reduced pyrimidine nucleotide concen-
trations. Therefore, we compared the amounts of two camps and De Clercq, 1978; Chen et al., 1993; Gutowski
et al., 1975), might be useful for treatment of seriousmRNAs, one of 500 nucleotides encoding the vaccinia
virus growth factor and the other of 4200 nucleotides poxvirus infections in humans.
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